These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34234742)

  • 1. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
    Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
    Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
    Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
    Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.
    Secreto G; Venturelli E; Meneghini E; Carcangiu ML; Paolini B; Agresti R; Pellitteri C; Berrino F; Gion M; Cogliati P; Saragò G; Micheli A
    BMC Cancer; 2012 Dec; 12():599. PubMed ID: 23241075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
    Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
    Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
    Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
    Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
    Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.
    Vera-Badillo FE; Templeton AJ; de Gouveia P; Diaz-Padilla I; Bedard PL; Al-Mubarak M; Seruga B; Tannock IF; Ocana A; Amir E
    J Natl Cancer Inst; 2014 Jan; 106(1):djt319. PubMed ID: 24273215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
    Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
    J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
    Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
    Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    Venturelli E; Orenti A; Fabricio ASC; Garrone G; Agresti R; Paolini B; Bonini C; Gion M; Berrino F; Desmedt C; Coradini D; Biganzoli E
    BMC Cancer; 2018 Jun; 18(1):651. PubMed ID: 29895278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the AR/ER ratio in ER-positive breast cancer patients.
    Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
    Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
    Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
    Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status.
    Vellaisamy G; Tirumalae R; Inchara YK
    J Cancer Res Ther; 2019; 15(5):989-993. PubMed ID: 31603099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer.
    Agrawal A; Ziolkowski P; Grzebieniak Z; Jelen M; Bobinski P; Agrawal S
    Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):550-5. PubMed ID: 26230371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
    J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
    Wellberg EA; Checkley LA; Giles ED; Johnson SJ; Oljira R; Wahdan-Alaswad R; Foright RM; Dooley G; Edgerton SM; Jindal S; Johnson GC; Richer JK; Kabos P; Thor AD; Schedin P; MacLean PS; Anderson SM
    Horm Cancer; 2017 Dec; 8(5-6):269-285. PubMed ID: 28741260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
    Elebro K; Bendahl PO; Jernström H; Borgquist S
    Breast Cancer Res Treat; 2017 Oct; 165(3):645-657. PubMed ID: 28643022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.